Shanghai Junshi Biosciences Co., Ltd (SHA: 688180), a China-based biotechnology firm, has announced an exclusive license and commercialization agreement with India-based Dr. Reddy’s Laboratories (BOM: 500124). The agreement focuses on the programmed death-1 (PD-1) inhibitor, Tuoyi (toripalimab), marking a significant step in the global expansion of this therapeutic agent.
Territorial Rights and Financial Terms of the Agreement
Dr. Reddy’s Laboratories is set to acquire exclusive development and commercial rights to Tuoyi in key territories including Brazil, Mexico, Colombia, Argentina, Peru, Chile, Panama, Uruguay, India, and South Africa. The Indian firm holds an option to expand the license to Australia, New Zealand, and 9 additional countries. The deal includes an upfront payment of USD 7 million, with an additional USD 3 million if Dr. Reddy extends the territorial scope, plus milestone payments of up to USD 718.3 million, and a double-digit percentage royalty on net sales of Tuoyi.
Tuoyi’s Market Filings and Partnerships
Tuoyi, China’s first domestic PD-1 inhibitor approved in December 2018 for melanoma, has received six indication approvals in China. The drug is currently under review in the US, EU, and UK for multiple market filings. This agreement with Dr. Reddy’s Laboratories is Junshi Biosciences’ third major partnership concerning Tuoyi rights, following previous collaborations with Coherus Biosciences for US and Canadian development, and with UK firm Hikma Pharmaceuticals PLC for 20 countries in the Middle East and North Africa.-Fineline Info & Tech
